Novel Antibody Targeting Fat-Tissue Hormone May Lead To Type 2 Diabetes Treatment

An anti-body developed by researchers to target a hormone in adipose tissue can be a potential new treatment for diabetes, says a new study.

Besides Type-2 diabetes, the new therapeutic that improves glucose regulation and reduces fatty liver could potentially be used to treat fatty liver disease, and other metabolic diseases, the study said.

Extracting Bone-Making Cells from Fat Tissue
A variety of cells found within our fat have potential to become bone, cartilage or more fat if they are properly prompted.

‘The antibody improves glucose regulation and reduces fatty liver in obese mice by targeting a hormone in adipose tissue called aP2 (also known as FABP4).’

Tweet it Now

These monoclonal antibodies have the potential to be transformative first-in-class therapeutics to fight obesity-related metabolic and immunometabolic disease, the researchers said.

The hormone in fat tissue that the antibody targets is called aP2 (also known as FABP4).

"The importance of this study is two-fold: first, demonstrating the importance of aP2 as a critical hormone in abnormal glucose metabolism, and secondly, showing that aP2 can be effectively targeted to treat diabetes and potentially other immunometabolic diseases," said Gokhan Hotamisligil, professor at Harvard T.H. Chan School of Public Health.

Bone Marrow Fat Tissue Secretes Hormone That Keeps the Body Healthy
Bone marrow fat has been known for its flavorful addition to soups and as a delicacy for dogs but it may also have untapped health benefits, new research finds.

The increase in adipose tissue characteristic of obesity has long been linked to increased risk for metabolic diseases such as Type-2 diabetes and cardiovascular disease.

Recently, it has become clear that the tissue itself plays an active role in metabolic disease, in part by releasing hormones which act in distant sites such as the liver, muscle, and brain that affect systemic metabolism.

Glucometers Going Wireless: The Impact of Wireless Technology on Diabetes Care
The recent launch of advanced wireless glucometers by two major healthcare companies can improve the quality of diabetes care.

In the new study, the researchers described the development and evaluation of novel monoclonal antibodies targeting the hormone aP2.

The team found that one of these antibodies effectively improved glucose regulation in two independent models of obesity.

Weight Loss Surgery Shows Potential to Reduce Risk of Diabetes and Heart Attacks
Bariatric surgery or weight loss surgery significantly improved existing Type 2 diabetes and lowered abnormally high blood pressure.

Additionally, beneficial reductions in liver fat were observed.

This work is still at the pre-clinical stage and will require extensive evaluation for safety and effectiveness before being considered for use in humans, the researchers pointed out.

The findings were detailed online in the journal Science Translational Medicine.

Source-IANS